Introduction
Influenza A viruses are respiratory pathogens that cause annual epidemics and occasional pandemics. The genome of influenza A viruses consists of eight segments of negative sense RNA with each segment encoding one (PB2, PA, HA, NP, and NA) or more (PB1, M, and NS) viral proteins. Influenza A viruses have two major surface antigens, the hemagglutinin (HA) and neuraminidase (NA) glycoproteins. Evolution of influenza viruses is thought to be predominantly driven by a host-mediated selective pressure that leads to changes at key antigenic sites, a mechanism known as antigenic drift.
1,2 A second process, known as antigenic shift, also contributes to the evolution of influenza viruses, though at a much lower frequency. Intrasubtype segment reassortment is a recurring feature of influenza virus evolution and has contributed to major antigenic changes in both influenza A(H3N2) 3 and A(H1N1). 4 In addition to vaccines, antiviral drugs provide valuable means for the management of influenza infections. Two classes of antiviral drugs, M2 blockers (amantadine and rimantadine) and NA inhibitors (oseltamivir and zanamivir), have been approved for use in the USA by the Food and Drug Administration in the prevention and control of influenza A virus infections. Resistance, intrinsic or acquired through drug selective pressure, can lessen effectiveness of antiviral drugs and thus are a cause for significant public health concern.
The M2 ion channel blockers amantadine and rimantadine, known collectively as adamantanes, were the first antiviral drugs available for prophylaxis and treatment of influenza A infections. Until recently, they have also been the most widely used anti-influenza drugs due to their low cost and over-the-counter availability in some countries. The molecular basis underlying resistance to this class of drugs has been well characterized. Adamantanes inhibit virus replication by blocking the proton channel formed by the M2 protein. [5] [6] [7] An amino acid change at any one of five residues in the transmembrane domain of this protein (positions 26, 27, 30, 31, or 34) confers cross-resistance to amantadine and rimantadine. 5, [8] [9] [10] Despite rapid emergence of drug-resistant mutants following treatment with adamantanes and the ability of drug-resistant mutants to transmit, 11 the incidence of adamantane resistance among viruses circulating in communities had been low (<1%) for decades. [12] [13] [14] [15] [16] At CDC, representative community isolates collected in various geographic regions during a given influenza season are tested for antiviral resistance. A dramatic rise in the frequency of adamantane resistance associated with an S31N mutation in the M2 protein was first reported for influenza A(H3N2) viruses circulating in Asia in 2000 17 which was followed by the spread of resistant A(H3N2) viruses to different parts of the world in subsequent seasons. [18] [19] [20] [21] [22] [23] Because of this, CDC recommended that adamantanes not be used for prophylaxis or treatment of influenza infections in the USA. 24 The genesis of adamantane resistance in influenza A(H3N2) viruses and mechanisms underlying their global spread have been the subject of intense scientific investigation. Adamantanes used locally during the SARS and avian flu scare in Asia might have contributed to the initial emergence of drug resistant virus variants in recent years; however, there is no evidence supporting the role of adamantanes usage in maintenance of adamantane resistant A(H3N2) viruses in human populations. Simonsen et al. 25 described possible evolutionary mechanisms, unrelated to drug selective pressure, which could lead to the globally increasing frequency of adamantane resistance in A(H3N2) influenza viruses. Based on a full genome phylogenetic survey, Simonsen et al. 25 concluded that the resistance-conferring S31N mutation did not come to dominance until it was put into a suitable genetic background via segment reassortment. This event led to the genesis of the adamantane-resistant 'N-lineage'. Viruses from this lineage circu- 100% among viruses circulating in several countries and was estimated at 96AE4% in the USA. 21 In the following season, the frequency of resistance was reduced in several but not all countries, for instance, it was estimated at 30AE1% in Canada and 86AE3% in the USA. 16, 26, 27 In addition to the variance in frequency of resistance, we observed co-circulation of several antigenic variants identified by HA inhibition assay (data not shown). The present study is aimed at investigating whether the decreased frequency in resistance among A(H3N2) viruses that circulated during 2006-2007 season was associated with the appearance of new genetic groups distinct from the N-lineage. The study also provides further insight into the nature of beneficial mutations responsible for the enhanced fitness of the adamantaneresistant A(H3N2) viruses and the genomic events underlying the genesis of these viruses. Table  S3 ). The 11 viruses from the 2007-2008 season were selected from the sample of 55 viruses to represent the wide range of the geographic diversity of these viruses.
Materials and methods

Virus isolates
Phylogenetic analysis
Phylogenetic analyses were performed using the Genetic Algorithm for Rapid Likelihood Inference (garli 0AE96b7), based on General Time Reversible (GTR) + I + c4 substitution model 28 and the tree analyzed in paup. 29 
Results
Reduction in adamantane resistance prevalence:
As a part of an ongoing strain surveillance activity, a total of 1451 A(H3N2) viruses circulating during 2006-2007 influenza season were tested for adamantane resistance. A pyrosequencing method was used to detect the presence of known markers of adamantane resistance in the M segment (M2 protein). The virus isolates originated from 46 countries with the majority from the USA, South America, and Asia ( Table 1 ). The resistance-conferring mutation S31N was detected in 73AE3% of the viruses collected globally, which reflects a substantial decrease compared to the overall frequency reported for the previous 2005-2006 influenza season. 21 A decline in adamantane resistance was especially noticeable in several geographic areas such as Hong Kong and Canada (from 100% to 69AE2%, and 100% to 30AE1%, respectively). In the USA, the decrease in resistance between the two seasons was less pronounced [from 96AE4% 
The gene segments encoding the remaining (internal) genes
The phylogenetic trees for the internal genomic segments There were two instances where the adamantane phenotype for a set of viruses was different from the remaining viruses in their clade. Within the adamantane resistant clade D, three isolates from New Mexico were sensitive. Based on sequence analysis, these isolates became adamantane sensitive through a reversion at amino acid 31 (N fi S). Inversely, two Canadian isolates from the adamantane sensitive clade B acquired the resistance mutation S31N (Figure 2A ). Clinical data indicate that the patients from whom these two viruses were collected were not treated with antiviral drugs.
With Figure 2C ). PA segment. The phylogeny of the polymerase complex PA gene ( Figure 2D ) showed that the genes from clades A, B, and D all descended from the N-lineage, sharing its seven characteristic markers. In contrast, the PA segment of viruses in clade C formed a separate grouping, which lacked all but one (Y437H) of those markers. NP segment. Based on the NP phylogenetic tree, only viruses from clade A cluster with the N-lineage ( Figure 2E ) having retained all its three characteristic markers A280V, I312V, and S377G (Table S1) Phylogenetic tree was constructed from the HA1 genes of viruses sequenced during the study (n = 64) and 36 viruses with full genome sequences available in public domain. Trees were inferred using maximum likelihood available in garli 0AE96b7 package. Using paup package bootstrap values, shown on tree branch nodes, were calculated from 100 replicates using of the data set to ensure robustness of the analysis (the results and parameters for each segments data set are available upon request). Phylogenetic trees throughout the manuscript were rooted with A ⁄ Beijing ⁄ 1 ⁄ 1968, which was used as an out-group. Viruses of genotype A appear to be direct descendants of the N-lineage viruses being closely related to them in all gene segments (Figure 3 ). Genotype A viruses kept all 17 characteristic markers of the N-lineage, 25 including three markers in the surface antigens HA and NA and the marker of adamantane resistance in M2 (Table S1 ). Additionally, viruses in genotype A acquired the change K31R in their NP gene.
In contrast, the genesis of the three remaining genotypes B, C, and D was due to independent reassortment events resulting in different constellations of the internal gene seg- Table  S2 .
Discussion
The 2006-2007 A(H3N2) influenza season saw the co-circulation of four distinct HA and NA clades which emerged due to antigenic drift from the predominant group of viruses (N-lineage) seen in the previous season. As deduced from whole genome sequence analysis, these four clades represented four different genotypes that had evolved through reassortment and ⁄ or mutations in the genes coding for non-glycosylated proteins. The co-circulation of these genotypes coincided with a noticeable reduction in resistance to adamantanes seen in A(H3N2) global surveillance Recently, Furuse et al. 31 reported that A(H3N2) viruses that viruses that circulated in Japan during 2006-2007 acquired adamantane sensitivity marker through reassortment.
Gene reassortment within the same influenza virus subtype is an integral part of influenza evolution and has been described in human, 3, 25, 32, 33 in avian, [34] [35] [36] in swine, 37, 38 and in the 1918 pandemic influenza viruses. 4, 39 In the 2005- (Figures 1 and 2) .
In It is worth noting that analysis of amino acid sequences of the surface glycoproteins from the 2006-2007 season viruses revealed presence of several changes at residues previously associated with antigenic positive selection. 40 These include R142G in the HA of A and B lineages, N144D in lineage A, and G50E and K140I in the D lineage. The latter lineage of viruses also acquired a unique change in NA (N387K) which is located in a region previously described as an antigenic site by Fanning et al. Despite the apparent antigenic advantage contributing to the fitness and dominance of this genotype, the continuing evolution of A(H3N2) viruses through reassortment remains highly plausible. If this genome fitness is maintained during antigenic evolution of H3N2 viruses, resistance to adamantanes could become fixed in circulating A(H3N2) viruses. The fact that there is no direct evidence that drug usage is required to maintain drug-resistance would favor such a possibility. Fixation of the adamantane-conferring resistance mutation S31N in swine influenza viruses in Europe lends credence to this possible scenario. 43 It should be noticed, however, that antigenic pressure among pigs is less intense than in the human population.
Although reassortment was responsible for the appearance of adamantane sensitive viruses in 2006-2007, there were also less-frequent reversion events that led to circulation of adamantane sensitive viruses. Conversely, adamantane resistance was acquired through mutation, S31N, of the M gene in a small number of viruses from adamantane-sensitive lineages. These observations underscore the degree of complexity of the mechanisms underlying the dynamics of adamantane resistance in seasonal influenza A viruses. Resistance to adamantanes was also reported in some groups of avian influenza A(H5N1) viruses isolated from humans and poultry in various countries. [44] [45] [46] This study demonstrates the importance of full genome sequencing and continued monitoring of resistance to available antivirals as well as the need to develop new antiinfluenza drugs and therapeutic approaches.
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